Amneal Pharmaceuticals (AMRX) Stock May Be Fully Priced Following Its 4.7x Run

Amneal Pharmaceuticals has turned in a very strong share price run over the last few years, yet its valuation checks lean expensive rather than cheap, which raises the question of how much of that strength is already reflected in the current price.

• Over the last three years the stock has returned about 4.7x, which sets a high bar for any further gains to be justified by business progress.
• The recent U.S. FDA approval that expands Amneal Pharmaceuticals’ iohexol injection portfolio can support expectations for its complex injectable business, but reliance on regulatory success and hospital demand leaves valuation exposed if these products underperform.
• Amneal Pharmaceuticals scores 2 out of 6 on the broader valuation checks, which suggests it leans expensive rather than standing out as a clear bargain on traditional metrics.

The issue now is whether Amneal Pharmaceuticals’ recent performance and product approvals are enough to justify the richer valuation signals investors are currently accepting.

Amneal Pharmaceuticals delivered 122.3% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

Is Amneal Pharmaceuticals Getting Expensive on Earnings?

P/E is a useful yardstick for Amneal Pharmaceuticals because the company is currently profitable, so the share price can be compared directly with its reported earnings.

On this measure, Amneal Pharmaceuticals trades on a P/E of about 46.8x, which is more than double the broader Pharmaceuticals industry average of 14.9x and well above the peer group average of 20.9x. The implied fair P/E from the broader checks sits lower at around 36.0x, so the current multiple carries a sizeable premium even after adjusting for factors such as growth expectations, margins, size and risk.

Despite the recent FDA approval expanding Amneal Pharmaceuticals’ iohexol injection portfolio, the market is already assigning a relatively high level of optimism at this earnings multiple compared with sector norms and the modelled fair ratio.

Overall, Amneal Pharmaceuticals stock currently trades on a P/E multiple that appears elevated relative to these comparison points.

See what the numbers say about this price — find out in our valuation breakdown.

The Amneal Pharmaceuticals Narrative: What Would Justify Today’s Price?

For Amneal Pharmaceuticals, Simply Wall St Narratives pick up where the valuation puzzle leaves off. They spell out which combinations of future growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price, and how different views on those paths can lead to very different outcomes. Each narrative ties its number to a concrete view of where growth, margins and risks go next, which you can come back to as new information arrives.

One of the top community narratives on Amneal Pharmaceuticals: 22% undervalued

“Vertical integration in biosimilars, including planned manufacturing capacity growth from 26,000 liters in 2026 to 75,000 liters by 2028, is intended to support 3 to 5 biosimilar developments annually…”

Read one of the top narratives on Amneal Pharmaceuticals

Do you think there’s more to the story for Amneal Pharmaceuticals? Head over to our Community to see what others are saying!

The Bottom Line

For Amneal Pharmaceuticals, the current P/E premium and low value score together point to a stock that screens overvalued on market multiples rather than clearly cheap. After such a strong three year share price move, the key question is whether earnings and margins can keep up with the expectations reflected in that higher multiple. The debate from here largely comes down to whether Amneal Pharmaceuticals can turn its product approvals and pipeline into durable profitability that makes today’s rich valuation look more reasonable, or whether the multiple eventually settles closer to industry norms.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com